A federal appeals court on Friday reinstated a 2017 jury verdict that required Teva Pharmaceutical Industries Ltd to pay GlaxoSmithKline Plc more than US$235 million for infringing a patent for its blood pressure drug Coreg.
US appeals court revives Glaxo US$235.5 million verdict against Teva
